The physiology, pharmacology and future of p2x7 as an analgesic drug target: Hype or promise?

Current Pharmaceutical Biotechnology

Volumn 12, Issue 10, 2011, Pages 1698-1706

  Bhattacharya, Anindya ^a   Neff, Robert A ^a   Wickenden, Alan D ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Il 1 ; Inflammation; P2x7; Pain; Purinergic

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; A 438079; A 740003; A 804598; A 839977; AFC 5128; ANALGESIC AGENT; AZ 1164537; AZD 9056; CE 224535; EVT 401; GSK 314181; GW 701343; GW 791343; INTERLEUKIN 1BETA; PURINERGIC P2X7 RECEPTOR; UNCLASSIFIED DRUG;

ALLODYNIA; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; NEUROPATHIC PAIN; NONHUMAN; PAIN; RHEUMATOID ARTHRITIS;

EID: 80053479970     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798357429     Document Type: Article

References (74)

1. Burnstock, G. Purinergic signalling and disorders of the central nervous system. Nat. Rev. Drug. Discov., 2008, 7(7), 575-590.
2. Rassendren, F.; Buell, G.N.; Virginio, C.; Collo, G.; North, R.A.; Surprenant, A. The permeabilizing ATP receptor, P2X7: cloning and expression of a human cDNA. J. Biol. Chem., 1997, 272(9), 5482-5486.
3. Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R.A.; Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science, 1996, 272(5262), 735-738.
4. Jarvis, M.F.; Khakh, B.S. ATP-gated P2X cation-channels. Neuropharmacology, 2009, 56(1), 208-215.
5. Abbracchio, M.P.; Burnstock, G.; Verkhratsky, A.; Zimmermann, H. Purinergic signalling in the nervous system: an overview. Trends Neurosci., 2009, 32(1), 19-29.
6. Surprenant, A.; North, R.A. Signaling at purinergic P2X receptors. Annu. Rev. Physiol., 2009, 71, 333-359.
7. Skaper, S.D.; Debetto, P.; Giusti, P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J., 2009, 24(2), 337-345.
8. Norenberg, W.; Schunk, J.; Fischer, W.; Sobottka, H.; Riedel, T.; Oliveira, J.F.; Franke, H.; Illes, P. Electrophysiological classification of P2X7 receptors in rat cultured neocortical astroglia. Br. J. Pharmacol., 2010, 160(8), 1941-1952.
9. Sim, J.A.; Young, M.T.; Sung, H.Y.; North, R.A.; Surprenant, A. Reanalysis of P2X7 receptor expression in rodent brain. J. Neurosci., 2004, 24(28), 6307-6314.
10. Anderson, C.M.; Nedergaard, M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci., 2006, 29(5), 257-262.
11. Buell, G.N.; Talabot, F.; Gos, A.; Lorenz, J.; Lai, E.; Morris, M.A.; Antonarakis, S.E. Gene structure and chromosomal localization of the human P2X7 receptor. Receptors Channels, 1998, 5(6), 347-354.
12. Young, M.T.; Pelegrin, P.; Surprenant, A. Identification of Thr283 as a key determinant of P2X7 receptor function. Br. J. Pharmacol., 2006, 149(3), 261-268.
13. Young, M.T.; Pelegrin, P.; Surprenant, A. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol. Pharmacol., 2007, 71(1), 92-100.
14. Browne, L.E.; Jiang, L.H.; North, R.A. New structure enlivens interest in P2X receptors. Trends Pharmacol. Sci., 2010, 31(5), 229-237.
15. Guo, C.; Masin, M.; Qureshi, O.S.; Murrell-Lagnado, R.D. Evidence for functional P2X4/P2X7 heteromeric receptors. Mol. Pharmacol., 2007, 72(6), 1447-1456.
16. Kawate, T.; Michel, J.C.; Birdsong, W.T.; Gouaux, E. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature, 2009, 460(7255), 592-598.
17. Chessell, I.P.; Simon, J.; Hibell, A.D.; Michel, A.D.; Barnard, E.A.; Humphrey, P.P. Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett., 1998, 439(1-2), 26-30.
18. Fonfria, E.; Clay, W.C.; Levy, D.S.; Goodwin, J.A.; Roman, S.; Smith, G.D.; Condreay, J.P.; Michel, A.D. Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue. Br. J. Pharmacol., 2008, 153(3), 544-556.
19. Michel, A.D.; Ng, S.W.; Roman, S.; Clay, W.C.; Dean, D.K.; Walter, D.S. Mechanism of action of species-selective P2X(7) receptor antagonists. Br. J. Pharmacol., 2009, 156(8), 1312-1325.
20. Jiang, L.H.; Kim, M.; Spelta, V.; Bo, X.; Surprenant, A.; North, R.A. Subunit arrangement in P2X receptors. J. Neurosci., 2003, 23(26), 8903-8910.
21. Michel, A.D.; Chambers, L.J.; Clay, W.C.; Condreay, J.P.; Walter, D.S.; Chessell, I.P. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br. J. Pharmacol., 2007, 151(1), 103-114.
22. Egan, T.M.; Khakh, B.S. Contribution of calcium ions to P2X channel responses. J. Neurosci., 2004, 24(13), 3413-3420.
23. North, R.A. Molecular physiology of P2X receptors. Physiol. Rev., 2002, 82(4), 1013-1067.
24. Virginio, C.; Church, D.; North, R. A.; Surprenant, A. Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacol., 1997, 36(9), 1285-1294.
25. Pelegrin, P.; Surprenant, A. The P2X(7) receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal, 2009, 5(2), 129-137.
26. Virginio, C.; MacKenzie, A.; North, R.A.; Surprenant, A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J. Physiol., 1999, 519 Pt 2, 335-346.
27. Hibell, A.D.; Kidd, E.J.; Chessell, I.P.; Humphrey, P.P.; Michel, A.D. Apparent species differences in the kinetic properties of P2X(7) receptors. Br. J. Pharmacol., 2000, 130(1), 167-173.
28. Hibell, A.D.; Thompson, K.M.; Simon, J.; Xing, M.; Humphrey, P.P.; Michel, A.D. Species- and agonist-dependent differences in the deactivation-kinetics of P2X7 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2001, 363(6), 639-648.
29. Chessell, I.P.; Michel, A.D.; Humphrey, P.P. Effects of antagonists at the human recombinant P2X7 receptor. Br. J. Pharmacol., 1998, 124(6), 1314-1320.
30. Ramirez, A.N.; Kunze, D.L. P2X purinergic receptor channel expression and function in bovine aortic endothelium. Am. J. Physiol. Heart. Circ. Physiol., 2002, 282(6), H2106-2116.
31. Iglesias, R.; Locovei, S.; Roque, A.; Alberto, A.P.; Dahl, G.; Spray, D.C.; Scemes, E. P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am. J. Physiol. Cell. Physiol., 2008, 295(3), C752-760.
32. Pelegrin, P.; Surprenant, A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO. J., 2006, 25(21), 5071-5082.
33. Jiang, L.H.; Rassendren, F.; Mackenzie, A.; Zhang, Y.H.; Surprenant, A.; North, R.A. N-methyl-D-glucamine and propidium dyes utilize different permeation pathways at rat P2X(7) receptors. Am. J. Physiol. Cell. Physiol., 2005, 289(5), C1295-1302.
34. Monif, M.; Reid, C.A.; Powell, K.L.; Smart, M.L.; Williams, D.A. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J. Neurosci., 2009, 29(12), 3781-3791.
35. Di Virgilio, F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol. Sci., 2007, 28(9), 465-472.
36. Ogura, Y.; Sutterwala, F.S.; Flavell, R.A. The inflammasome: first line of the immune response to cell stress. Cell, 2006, 126(4), 659-662.
37. Ferrari, D.; Pizzirani, C.; Adinolfi, E.; Lemoli, R.M.; Curti, A.; Idzko, M.; Panther, E.; Di Virgilio, F. The P2X7 Receptor: A Key Player in IL-1 Processing and Release. J. Immunol., 2006, 176(7), 3877-3883.
38. Ward, J.R.; West, P.W.; Ariaans, M.P.; Parker, L.C.; Francis, S.E.; Crossman, D.C.; Sabroe, I.; Wilson, H.L. Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms. J. Biol. Chem., 2010, 285(30), 23147-23158.
39. Griffiths, R.J.; Stam, E.J.; Downs, J.T.; Otterness, I.G. ATP induces the release of IL-1 from LPS-primed cells in vivo. J. Immunol., 1995, 154(6), 2821-2828.
40. Labasi, J.M.; Petrushova, N.; Donovan, C.; McCurdy, S.; Lira, P.; Payette, M.M.; Brissette, W.; Wicks, J.R.; Audoly, L.; Gabel, C.A. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol., 2002, 168(12), 6436-6445.
41. Solle, M.; Labasi, J.; Perregaux, D.G.; Stam, E.; Petrushova, N.; Koller, B.H.; Griffiths, R.J.; Gabel, C.A. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem., 2001, 276(1), 125-132.
42. Honore, P.; Donnelly-Roberts, D.; Namovic, M.; Zhong, C.; Wade, C.; Chandran, P.; Zhu, C.; Carroll, W.; Perez-Medrano, A.; Iwakura, Y.; Jarvis, M.F. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1[alpha][beta] knockout mice. Behav. Brain Res., 2009, 204(1), 77-81.
43. Di Virgilio, F.; Ceruti, S.; Bramanti, P.; Abbracchio, M.P. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci., 2009, 32(2), 79-87.
44. Browne, L.E.; Jiang, L.H.; North, R.A. New structure enlivens interest in P2X receptors. Trends Pharmacol. Sci., 2010, 31(5), 229-237.
45. Michel, A.D.; Chambers, L.J.; Walter, D.S. Negative and positive allosteric modulators of the P2X(7) receptor. Br. J. Pharmacol., 2008, 153(4), 737-750.
46. Furber, M.; Alcaraz, L.; Bent, J.E.; Beyerbach, A.; Bowers, K.; Braddock, M.; Caffrey, M.V.; Cladingboel, D.; Collington, J.; Donald, D.K.; Fagura, M.; Ince, F.; Kinchin, E.C.; Laurent, C.; Lawson, M.; Luker, T.J.; Mortimore, M.M.P.; Pimm, A.D.; Riley, R.J.; Roberts, N.; Robertson, M.; Theaker, J.; Thorne, P.V.; Weaver, R.; Webborn, P.; Willis, P. Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X7 Receptor Antagonists/ Interleukin-1β Inhibitors. J. Med. Chem., 2007, 50(24), 5882-5885.
47. Michel, A.D.; Xing, M.; Thompson, K.M.; Jones, C.A.; Humphrey, P.P.A. Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. Eur. J. Pharmacol., 2006, 534(1-3), 19-29.
48. Donnelly-Roberts, D.L.; Namovic, M.T.; Surber, B.; Vaidyanathan, S.X.; Perez-Medrano, A.; Wang, Y.; Carroll, W.A.; Jarvis, M.F. [(3)H]A-804598 ([(3)H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacol., 2009, 56(1), 223-229.
49. Donnelly-Roberts, D.L.; Namovic, M.T.; Han, P.; Jarvis, M.F. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. Pharmacol., 2009, 157(7), 1203-1214.
50. Bhattacharya, A.; Maher, M. W., E.; Olafson, T.; Wang, Q.; Ao, H.; Wu, N.; Neff, R.; Freedman, J.; Lebsack, A.; Jones, W.; Hawryluk, N.; Wickenden, A. In Experimental Biology: Anaheim, CA, 2010.
51. Stokes, L.; Jiang, L.H.; Alcaraz, L.; Bent, J.; Bowers, K.; Fagura, M.; Furber, M.; Mortimore, M.; Lawson, M.; Theaker, J.; Laurent, C.; Braddock, M.; Surprenant, A. Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br. J. Pharmacol., 2006, 149(7), 880-887.
52. Clark, A.K.; Staniland, A.A.; Marchand, F.; Kaan, T.K.Y.; McMahon, S.B.; Malcangio, M. P2X7-Dependent Release of Interleukin- 1{beta} and Nociception in the Spinal Cord following Lipopolysaccharide. J. Neurosci., 2010, 30(2), 573-582.
53. Honore, P.; Wade, C.L.; Zhong, C.; Harris, R.R.; Wu, C.; Ghayur, T.; Iwakura, Y.; Decker, M.W.; Faltynek, C.; Sullivan, J.; Jarvis, M.F. Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav. Brain Res., 2006, 167(2), 355-364.
54. McMahon, S.B.; Malcangio, M. Current challenges in glia-pain biology. Neuron, 2009, 64(1), 46-54.
55. Reeve, A.J.; Patel, S.; Fox, A.; Walker, K.; Urban, L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur. J. Pain, 2000, 4(3), 247-257.
56. Wolf, G.; Gabay, E.; Tal, M.; Yirmiya, R.; Shavit, Y. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain, 2006, 120(3), 315-324.
57. Chessell, I.P.; Hatcher, J.P.; Bountra, C.; Michel, A.D.; Hughes, J.P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W.L.; Grahames, C.B.; Casula, M.A.; Yiangou, Y.; Birch, R.; Anand, P.; Buell, G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain, 2005, 114(3), 386-396.
58. Ando, R.; Mehesz, B.; Gyires, K.; Illes, P.; Sperlagh, B. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br. J. Pharmacol., 2010, 159, 1106-1117.
59. Teixeira, J.M.; Oliveira, M.C.; Parada, C.A.; Tambeli, C.H. Peripheral mechanisms underlying the essential role of P2X7 receptors in the development of inflammatory hyperalgesia. Eur. J. Pharmacol., 2010, 644(1-3), 55-60.
60. Honore, P.; Donnelly-Roberts, D.; Namovic, M.T.; Hsieh, G.; Zhu, C.Z.; Mikusa, J.P.; Hernandez, G.; Zhong, C.; Gauvin, D.M.; Chandran, P.; Harris, R.; Medrano, A.P.; Carroll, W.; Marsh, K.; Sullivan, J.P.; Faltynek, C.R.; Jarvis, M.F. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol.Exp. Ther., 2006, 319(3), 1376-1385.
61. Broom, D.C.; Matson, D.J.; Bradshaw, E.; Buck, M.E.; Meade, R.; Coombs, S.; Matchett, M.; Ford, K.K.; Yu, W.; Yuan, J.; Sun, S.H.; Ochoa, R.; Krause, J.E.; Wustrow, D.J.; Cortright, D.N. Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benz amide, a P2X7 Antagonist in Animal Models of Pain and Inflammation. J. Pharmacol. Exp. Ther., 2008, 327(3), 620-633.
62. Lappin SCW.L., Clayton N, Chambers LJ, Demont EH, Chessell IP, Richardson; JC, G.M. In Society for Neuroscience: Washington, DC, 2005.
63. McGaraughty, S.; Chu, K.L.; Namovic, M.T.; Donnelly-Roberts, D.L.; Harris, R.R.; Zhang, X.F.; Shieh, C.C.; Wismer, C.T.; Zhu, C.Z.; Gauvin, D.M.; Fabiyi, A.C.; Honore, P.; Gregg, R.J.; Kort, M.E.; Nelson, D.W.; Carroll, W.A.; Marsh, K.; Faltynek, C.R.; Jarvis, M.F. P2X7-related modulation of pathological nociception in rats. Neuroscience, 2007, 146(4), 1817-1828.
64. Nelson, D.W.; Sarris, K.; Kalvin, D.M.; Namovic, M.T.; Grayson, G.; Donnelly-Roberts, D.L.; Harris, R.; Honore, P.; Jarvis, M.F.;& Faltynek, C.R.; Carroll, W.A. Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists. J Med. Chem., 2008, 51(10), 3030-3034.
65. McInnes IBS.N., Perrett JH, Parmar H, Wang MM, Astbury C. In American College of Rheumatology: Boston, MA, 2007.
66. Abdi, M.H.; Beswick, P.J.; Billinton, A.; Chambers, L.J.; Charlton, A.; Collins, S.D.; Collis, K.L.; Dean, D.K.; Fonfria, E.; Gleave, R.J.; Lejeune, C.L.; Livermore, D.G.; Medhurst, S.J.; Michel, A.D.; Moses, A.P.; Page, L.; Patel, S.; Roman, S.A.; Senger, S.; Slingsby, B.; Steadman, J.G.; Stevens, A.J.; Walter, D.S. Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett., 2010, 20(17), 5080-5084.
67. Chambers, L.J.; Stevens, A.J.; Moses, A.P.; Michel, A.D.; Walter, D.S.; Davies, D.J.; Livermore, D.G.; Fonfria, E.; Demont, E.H.; Vimal, M.; Theobald, P.J.; Beswick, P.J.; Gleave, R.J.; Roman, S.A.; Senger, S. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett., 2010, 20(10), 3161-3164.
68. Chen, X.; Pierce, B.; Naing, W.; Grapperhaus, M.L.; Phillion, D.P. Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl) methyl)-5-(5-fluoropyrimidin -2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. Bioorg. Med. Chem. Lett., 2010, 20(10), 3107-3111.
69. Carroll, W.A.; Donnelly-Roberts, D.; Jarvis, M.F. Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal, 2009, 5(1), 63-73.
70. Jarvis, M.F. The neural-glial purinergic receptor ensemble in chronic pain states. Trends Neurosci., 2010, 33(1), 48-57.
71. Hughes, J.P.; Hatcher, J.P.; Chessell, I.P. The role of P2X(7) in pain and inflammation. Purinergic Signal, 2007, 3(1-2), 163-169.
72. Lister, M.F.; Sharkey, J.; Sawatzky, D.A.; Hodgkiss, J.P.; Davidson, D.J.; Rossi, A.G.; Finlayson, K. The role of the purinergic P2X7 receptor in inflammation. J. Inflamm. (Lond), 2007, 4, 5.
73. Donnelly-Roberts, D.L.; Jarvis, M.F. Discovery of P2X7 receptorselective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br. J. Pharmacol., 2007, 151(5), 571-579.
74. Abberley, L.; Bebius, A.; Beswick, P.J.; Billinton, A.; Collis, K.L.; Dean, D.K.; Fonfria, E.; Gleave, R.J.; Medhurst, S.J.; Michel, A.D.; Moses, A.P.; Patel, S.; Roman, S.A.; Scoccitti, T.; Smith, B.; Steadman, J.G.A.; S.Walter, D. Identification of 2-oxo-N- (phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett., 2010, 20(22), 6370-6374